Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $8.00 Average Price Target from Analysts

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have earned a consensus recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $8.00.

SANA has been the topic of several analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley initiated coverage on shares of Sana Biotechnology in a report on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 target price on the stock.

Sana Biotechnology Stock Down 0.7%

Shares of NASDAQ:SANA opened at $2.96 on Friday. The firm’s 50 day moving average price is $3.71 and its 200 day moving average price is $2.70. The stock has a market cap of $703.92 million, a price-to-earnings ratio of -2.79 and a beta of 1.88. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04. On average, equities analysts anticipate that Sana Biotechnology will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Several hedge funds have recently added to or reduced their stakes in the stock. Viewpoint Capital Management LLC increased its stake in Sana Biotechnology by 19.1% in the second quarter. Viewpoint Capital Management LLC now owns 28,045 shares of the company’s stock valued at $77,000 after purchasing an additional 4,500 shares during the last quarter. Captrust Financial Advisors increased its stake in Sana Biotechnology by 43.8% in the second quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock valued at $43,000 after purchasing an additional 4,807 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Sana Biotechnology by 46.9% in the second quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company’s stock valued at $42,000 after purchasing an additional 4,931 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Sana Biotechnology by 2.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 280,731 shares of the company’s stock valued at $457,000 after purchasing an additional 6,613 shares during the last quarter. Finally, Summit X LLC increased its stake in Sana Biotechnology by 18.5% in the second quarter. Summit X LLC now owns 42,665 shares of the company’s stock valued at $116,000 after purchasing an additional 6,665 shares during the last quarter. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.